Ulyanovsk Medico-biological Journal

CLINICAL MEDICINE

Download  article

DOI 10.34014/2227-1848-2021-1-71-83

 

"TRUE" INCIDENCE OF SKIN MELANOMA, BASED ON A MASSIVE 3-DAY EARLY DIAGNOSIS CAMPAIGN IN A BIG INDUSTRIAL CITY

 

E.Yu. Neretin1,2, S.Kh. Sadreeva3

1 Samara Regional Clinical Oncological Dispensary, Samara, Russia;

2 Medical University "Reaviz", Samara, Russia;

3 Samara State Medical University, Samara, Russia

 

Skin melanoma (SM) is a malignant tumor that is quite rarely diagnosed in Russia. However, both absolute and relative numbers (incidence) of patients with this diagnosis are growing. The trend persists for many years, but the official incidence rate does not reflect the true picture, so it is likely to be lower than the true one.

The aim of the study was to calculate the assumed incidence of skin melanoma based on the data from a large-scale early diagnosis campaign.

Materials and Methods. In 2019, 800 patients were examined during a 3-day campaign in the Samara region. A non-invasive diagnostic method (digital dermatoscopy), a multi-agent technology based on artificial intelligence and a proprietary technology (patent No. 2018620399, No. 2018613016) were used during the campaign. Four skin melanomas were identified at an early, pre-invasive stage.

Results. Two different methods (depending on the percentage of population coverage and the campaign duration), made it possible to calculate a true indicator of the skin melanoma incidence.

Conclusion. It was possible to adjust the "true" incidence rate of skin melanoma. In 2019, it ranged from 9.65 to 15.31 per 100 000 people, which is significantly higher than the official rate registered that year (8.11 per 100 000 population).

Keywords: skin melanoma, true incidence, large-scale campaign, multi-agent system, skin melanoma modeling.

Conflict of interest. The authors declare no conflict of interest.

 

References

  1. Ward-Peterson M., Acuсa J.M., Alkhalifah M.K, Nasiri A.M., Al-Akeel E.S., Alkhaldi T.M., Dawari S.A., Aldaham S.A. Association Between Race/Ethnicity and Survival of Melanoma Patients in the United States Over 3 Decades: A Secondary Analysis of SEER Data. Medicine (Baltimore). 2016; 95 (17): e3315. DOI: 10.1097/MD.0000000000003315.

  2. A. Ferhat Misir, Mustafa C. Durmuşlar, Tamer Zerener, Banu D. Gün. Primary malignant melanoma. PMID: 27052289. PMCID: PMC4852024. DOI: 10.15537/smj.2016.4.15017.

  3. Marco Rastrelli, Saveria Tropea, Carlo Riccardo Rossi, Mauro Alaibac. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. PMID: 25398793.

  4. Dirk Schadendorf, Alexander C.J. van Akkooi, Carola Berking, Klaus G Griewank, Ralf Gutzmer, Axel Hauschild, Andreas Stang, Alexander Roesch, Selma Ugurel. Melanoma. Lancet. 2018; 392 (10151): 971–984. DOI: 10.1016/S0140-6736(18)31559-9.

  5. Goyal M., Knackstedt T., Yan S., Hassanpour S. Artificial intelligence-based image classification methods for diagnosis of skin cancer: Challenges and opportunities. Comput. Biol Med. 2020; 127: 104065. DOI: 10.1016/j.compbiomed.2020.104065.

  6. Felmingham, Nikki R. Adler, Zongyuan Ge, Rachael L. Morton, Monika Janda, Victoria J. Mar. The Importance of Incorporating Human Factors in the Design and Implementation of Artificial Intelligence for Skin Cancer Diagnosis in the Real World Claire. Am. J. Clin. Dermatol. 2020; 22. DOI: 10.1007/s40257-020-00574-4.

  7. Elizabeth Ann. L. Enninga, Justin C. Moser, Amy L. Weaver, Svetomir N. Markovic, Jerry D. Brewer, Alexey A. Leontovich, Tina J. Hieken, Lynne Shuster, Lisa A. Kottschade, Ariadna Olariu, Aaron S. Mansfield, Roxana S. Dronca. Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cancer Med. 2017; 6 (10): 2203–2212. DOI: 10.1002/cam4.1152.

  8. Adler N.R., Kelly J.W., Guitera P., Menzies S.W., Chamberlain A.J., Fishburn P., Button-Sloan A.E., Heal C., Soyer H.P., Thompson J.F. Methods of melanoma detection and of skin monitoring for individuals at high risk of melanoma: new Australian clinical practice. Med. J. Aust. 2019; 210 (1): 41–47. DOI: 10.5694/mja2.12033.

  9. Đorđević Brlek Z., Jurakić Tončić R., Radoš J., Marinović B. Dermoscopy of Nodular Melanoma: Review of the Literature and Report of 3 Cases. Acta Dermatovenerol. Croat. 2016; 24 (3): 203–208.

  10. Detrixhe A., Libon F., Mansuy M., Nikkels-Tassoudji N., Rorive A., Arrese J.E., Quatresooz P., Reginster M.A., Nikkels A.F. Melanoma masquerading as nonmelanocytic lesions. Melanoma Res. 2016; 26 (6): 631–634. DOI: 10.1097/CMR.0000000000000294.PMID: 27537773.

  11. Curković D., Pastar Z., Kostović K. Dermoscopy and Early Melanoma. Coll. Antropol. 2015; 39 (3): 791–795.

  12. Lallas A., Apalla Z., Ioannides D., Lazaridou E., Kyrgidis A., Broganelli P., Alfano R., Zalaudek I., Argenziano G. Update on dermoscopy of Spitz/Reed naevi and management guidelines by the International Dermoscopy Society.; International Dermoscopy Society. Br. J. Dermatol. 2017; 177 (3): 645–655. DOI: 10.1111/bjd.15339.

  13. Holme S.A. GPs have role in early detection of melanoma. Practitioner. 2013; 257 (1762): 27–30.

  14. Brunssen A., Waldmann A., Eisemann N., Katalinic A.J. Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: A systematic review. Am. Acad. Dermatol. 2017; 76 (1): 129–139. DOI: 10.1016/j.jaad.2016.07.045.

  15. Wernli K.J., Henrikson N.B., Morrison C.C., Nguyen M., Pocobelli G., Blasi P.R. Screening for Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016; 316 (4): 436–447. DOI: 10.1001/jama.2016.5415.

  16. Shellenberger R., Nabhan M., Kakaraparthi S. Melanoma screening: A plan for improving early detection. Ann. Med. 2016; 48 (3): 142–148. DOI: 10.3109/07853890.2016.1145795.

  17. Eisemann N., Waldmann A., Holleczek B., Katalinic A.J. Observed and expected mortality in the German skin cancer screening pilot project SCREEN. Med. Screen. 2018; 25 (3): 166–168. DOI: 10.1177/0969141317734003.

  18. Wernli K.J., Henrikson N.B., Morrison C.C., Nguyen M., Pocobelli G., Whitlock E.P. Rockville (MD) Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force: Report of Agency for Healthcare Research and Quality (US) № 14-05210-EF-1; 2016.

  19. Stang A., Jöckel K.H. Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany. Cancer. 2016; 122 (3): 432–437. DOI: 10.1002/cncr.29755.

  20. Marghoob N.G., Liopyris K., Jaimes N.J. Dermoscopy: A Review of the Structures That Facilitate Mela­noma Detection. Am. Osteopath. Assoc. 2019; 119 (6): 380–390. DOI: 10.7556/jaoa.2019.067.

Received 11 January 2021; accepted 03 February 2021.

 

Information about the authors

Neretin Evgeniy Yur'evich, Candidate of Sciences (Medicine), High Level Certificate Oncologist, Samara Regional Clinical Oncological Dispensary. 443031, Russia, Samara, Chapaevskaya St., 227; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0002-2316-7482

Sadreeva Saniya Khamzyanovna, Doctor of Sciences (Medicine), Professor, Chair of Public Health and Health Care, Samara State Medical University, Ministry of Health of the Russian Federation. 443099, Russia, Samara, Chapaevskaya St., 89; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0001-8278-3923

 

For citation

Neretin E.Yu., Sadreeva S.Kh. «Istinnaya» zabolevaemost' melanomoy kozhi po rezul'tatam masshtabnoy trekhdnevnoy kampanii po ranney diagnostike v krupnom promyshlennom tsentre ["True" incidence of skin melanoma, based on a massive 3-day early diagnosis campaign in a big industrial city]. Ul'yanovskiy mediko-biologicheskiy zhurnal. 2021; 1: 71–83. DOI: 10.34014/2227-1848-2021-1-71-83 (in Russian).

 

Скачать статью

УДК 616-006.6

DOI 10.34014/2227-1848-2021-1-71-83

 

«ИСТИННАЯ» ЗАБОЛЕВАЕМОСТЬ МЕЛАНОМОЙ КОЖИ ПО РЕЗУЛЬТАТАМ МАСШТАБНОЙ ТРЕХДНЕВНОЙ КАМПАНИИ ПО РАННЕЙ ДИАГНОСТИКЕВ КРУПНОМ ПРОМЫШЛЕННОМ ЦЕНТРЕ

 

Е.Ю. Неретин1,2, С.Х. Садреева3

1 ГБУЗ «Самарский областной клинический онкологический диспансер», г. Самара, Россия;

2 Частное учреждение образовательная организация высшего образования «Медицинский университет «Реавиз», г. Самара, Россия;

3 ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава РФ, г. Самара, Россия

 

Меланома кожи (МК) является злокачественной опухолью, которая встречается в РФ довольно редко, причем растет как абсолютное количество пациентов с данным диагнозом, так и относительное (заболеваемость). Данная тенденция стабильно сохраняется на протяжении многих лет, однако официальный показатель заболеваемости не отражает реальной картины и вполне вероятно, что он несколько ниже «истинного».

Целью исследования был расчет предполагаемой заболеваемости меланомой кожи на основании данных, полученных в результате масштабной кампании по ранней диагностике.

Материалы и методы. В Самарской области в 2019 г. была проведена 3-дневная кампания, которая позволила обследовать 800 обратившихся пациентов с помощью неинвазивного метода диагностики (цифровой дерматоскопии) и мультиагентной технологии, основанной на искусственном интеллекте и авторской методике (патент на изобретение № 2018620399, № 2018613016). Всего было выявлено 4 меланомы кожи на ранней, доинвазивной, стадии.

Результаты. В ходе расчета по 2 различным методикам (в зависимости от процента охвата населения и продолжительности акции) был получен «истинный» показатель заболеваемости МК.

Выводы. «Истинный» показатель заболеваемости МК был скорректирован и составил от 9,65 до 15,31 на 100 тыс. населения, что значительно больше официального, зарегистрированного в отчетном 2019 г. (8,11 на 100 тыс. населения).

Ключевые слова: меланома кожи, «истинная» заболеваемость, масштабная кампания, мультиагентная система, моделирование заболеваемости меланомы кожи.

 

Литература

  1. Ward-Peterson M., Acuсa J.M., Alkhalifah M.K, Nasiri A.M., Al-Akeel E.S., Alkhaldi T.M., Dawari S.A., Aldaham S.A. Association Between Race/Ethnicity and Survival of Melanoma Patients in the United States Over 3 Decades: A Secondary Analysis of SEER Data. Medicine (Baltimore). 2016; 95 (17): e3315. DOI: 10.1097/MD.0000000000003315.

  2. A. Ferhat Mısır, Mustafa C. Durmuşlar, Tamer Zerener, Banu D. Gün. Primary malignant melanoma. PMID: 27052289. PMCID: PMC4852024. DOI: 10.15537/smj.2016.4.15017.

  3. Marco Rastrelli, Saveria Tropea, Carlo Riccardo Rossi, Mauro Alaibac. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. PMID: 25398793.

  4. Dirk Schadendorf, Alexander C.J. van Akkooi, Carola Berking, Klaus G Griewank, Ralf Gutzmer, Axel Hauschild, Andreas Stang, Alexander Roesch, Selma Ugurel. Melanoma. Lancet. 2018; 392 (10151): 971–984. DOI: 10.1016/S0140-6736(18)31559-9.

  5. Goyal M., Knackstedt T., Yan S., Hassanpour S. Artificial intelligence-based image classification methods for diagnosis of skin cancer: Challenges and opportunities. Comput. Biol Med. 2020; 127: 104065. DOI: 10.1016/j.compbiomed.2020.104065.

  6. Felmingham, Nikki R. Adler, Zongyuan Ge, Rachael L. Morton, Monika Janda, Victoria J. Mar. The Importance of Incorporating Human Factors in the Design and Implementation of Artificial Intelligence for Skin Cancer Diagnosis in the Real World Claire. Am. J. Clin. Dermatol. 2020; 22. DOI: 10.1007/s40257-020-00574-4.

  7. Elizabeth Ann. L. Enninga, Justin C. Moser, Amy L. Weaver, Svetomir N. Markovic, Jerry D. Brewer, Alexey A. Leontovich, Tina J. Hieken, Lynne Shuster, Lisa A. Kottschade, Ariadna Olariu, Aaron S. Mansfield, Roxana S. Dronca. Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cancer Med. 2017; 6 (10): 2203–2212. DOI: 10.1002/cam4.1152.

  8. Adler N.R., Kelly J.W., Guitera P., Menzies S.W., Chamberlain A.J., Fishburn P., Button-Sloan A.E., Heal C., Soyer H.P., Thompson J.F. Methods of melanoma detection and of skin monitoring for individuals at high risk of melanoma: new Australian clinical practice. Med. J. Aust. 2019; 210 (1): 41–47. DOI: 10.5694/mja2.12033.

  9. Đorđević Brlek Z., Jurakić Tončić R., Radoš J., Marinović B. Dermoscopy of Nodular Melanoma: Review of the Literature and Report of 3 Cases. Acta Dermatovenerol. Croat. 2016; 24 (3): 203–208.

  10. Detrixhe A., Libon F., Mansuy M., Nikkels-Tassoudji N., Rorive A., Arrese J.E., Quatresooz P., Reginster M.A., Nikkels A.F. Melanoma masquerading as nonmelanocytic lesions. Melanoma Res. 2016; 26 (6): 631–634. DOI: 10.1097/CMR.0000000000000294.PMID: 27537773.

  11. Curković D., Pastar Z., Kostović K. Dermoscopy and Early Melanoma. Coll. Antropol. 2015; 39 (3): 791–795.

  12. Lallas A., Apalla Z., Ioannides D., Lazaridou E., Kyrgidis A., Broganelli P., Alfano R., Zalaudek I., Argenziano G. Update on dermoscopy of Spitz/Reed naevi and management guidelines by the International Dermoscopy Society.; International Dermoscopy Society. Br. J. Dermatol. 2017; 177 (3): 645–655. DOI: 10.1111/bjd.15339.

  13. Holme S.A. GPs have role in early detection of melanoma. Practitioner. 2013; 257 (1762): 27–30.

  14. Brunssen A., Waldmann A., Eisemann N., Katalinic A.J. Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: A systematic review. Am. Acad. Dermatol. 2017; 76 (1): 129–139. DOI: 10.1016/j.jaad.2016.07.045.

  15. Wernli K.J., Henrikson N.B., Morrison C.C., Nguyen M., Pocobelli G., Blasi P.R. Screening for Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016; 316 (4): 436–447. DOI: 10.1001/jama.2016.5415.

  16. Shellenberger R., Nabhan M., Kakaraparthi S. Melanoma screening: A plan for improving early detection. Ann. Med. 2016; 48 (3): 142–148. DOI: 10.3109/07853890.2016.1145795.

  17. Eisemann N., Waldmann A., Holleczek B., Katalinic A.J. Observed and expected mortality in the German skin cancer screening pilot project SCREEN. Med. Screen. 2018; 25 (3): 166–168. DOI: 10.1177/0969141317734003.

  18. Wernli K.J., Henrikson N.B., Morrison C.C., Nguyen M., Pocobelli G., Whitlock E.P. Rockville (MD) Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force: Report of Agency for Healthcare Research and Quality (US) № 14-05210-EF-1; 2016.

  19. Stang A., Jöckel K.H. Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany. Cancer. 2016; 122 (3): 432–437. DOI: 10.1002/cncr.29755.

  20. Marghoob N.G., Liopyris K., Jaimes N.J. Dermoscopy: A Review of the Structures That Facilitate Melanoma Detection. Am. Osteopath. Assoc. 2019; 119 (6): 380–390. DOI: 10.7556/jaoa.2019.067. PMID: 31135866.

Поступила в редакцию 11.01.2021, принята 03.02.2021.

 

Авторский коллектив

Неретин Евгений Юрьевич – кандидат медицинских наук, врач-онколог высшей категории, ГБУЗ «Самарский областной клинический онкологический диспансер». 443031, Россия, г. Самара, ул. Солнечная 50; доцент, частное учреждение образовательная организация высшего образования «Медицинский университет «Реавиз». 443001, Россия, г. Самара, ул. Чапаевская, 227; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0002-2316-7482

Садреева Сания Хамзяновна – доктор медицинских наук, профессор кафедры общественного здоровья и здравоохранения, ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России. 443099, Россия, г. Самара, ул. Чапаевская, 89; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0001-8278-3923

 

Образец цитирования

Неретин Е.Ю., Садреева С.Х. «Истинная» заболеваемость меланомой кожи по результатам масштабной трехдневной кампании по ранней диагностике в крупном промышленном центре. Ульяновский медико-биологический журнал. 2021; 1: 71–83. DOI: 10.34014/2227-1848-2021-1-71-83